An Important Message from Joey Porrello
A friend of Project ALS living with ALS
Thanks to you, the Project ALS Tomorrow is Tonight 24th annual gala raised close to $1 million that will directly support our current ALS therapeutics research programs aiming to bring the first effective treatments and a cure to people living with ALS, ASAP. The gala brought together hundreds of Project ALS supporters, people living with ALS and their caregivers and loved ones, and our top researchers to celebrate this year’s research progress and and our honored guests: Ben Stiller, Christine Taylor, and their children Ella and Quin. For their exceptional contribution to rational, aggressive, ALS research, Project ALS presented the family with the Project ALS Families Research Award.
The Taylor-Stiller family has been close friends of Project ALS since Jenifer Estess was diagnosed with ALS at the age of 35 and decided to found Project ALS with her sisters Valerie and Meredith in 1998. Over the last 25 years, Ben has helped put Project ALS on the map, Christine has served as a standout leader on our Board of Directors, and Ella and Quin have grown up sharing their love and light with our community. We are grateful for their love, support, generosity, and leadership.
2022 Project ALS Research Achievements
A recent NIH funded study shows that by 2040, we’ll see an almost 70% increase in ALS diagnoses worldwide—and that goes for the related neurodegenerative diseases as well: ALS, Alzheimer’s, Parkinson’s and Huntington’s. We need to intensify our research efforts now. We can do this only with your help. Here are the top three Project ALS research achievements you’ve made possible this year:
- Prosetin was developed by Project ALS researchers, medicinal chemists—by all of us– specifically for the treatment of ALS. prosetin was built to cross the blood-brain barrier, and reduce “ER stress”—a cell stress pathway that contributes to ALS disease progression. Thanks to the Project ALS family, prosetin in now in clinical trial for ALS.
- ASOs. ASOs are an emerging technology designed to reduce toxic proteins within motor neurons, the brain cells affected in ALS. This year, Project ALS and our partners in industry, have generated ASOs to treat several genetic forms of ALS.
- The Project ALS Therapeutics Core has improved laboratory models of human ALS. Better lab models mean we can screen ALS drug candidates faster, and with greater accuracy. Everyone knows we need better drug trials. our improved model systems will get us there faster.
In 2022, thanks to you, Project ALS better understands why ALS happens—and, more importantly, how we can turn basic discovery into powerful therapies.
Look at prosetin, a medicine developed at the Project ALS Therapeutics Core in clinical trial right now for the treatment of ALS. We must keep this momentum going and deliver the next prosetins to clinical trial in 2023.
We did this together—and we’re just getting started. The Project ALS Therapeutics Core looks forward to reporting back to the community on more progress in the next months. If you would like to make a donation to move our research forward faster, please give as you can.